Emerging Treatments and Research in RCC
-
Immunotherapy and Targeted Therapy: Daniel J. George, MD, discussed the treatment options for patients with favorable-risk versus intermediate- or high-risk RCC, emphasizing how risk assessment influences treatment decisions. This discussion took place during a Case-Based Roundtable® event on January 3rd, 2025.
-
CD8 Lymph Node Avidity Research: Peter Zang, MD, highlighted research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for treating patients with metastatic renal cell carcinoma, focusing on the response to immunotherapy. This was featured in a podcast episode of Emerging Experts on March 1st, 2024.
-
LITESPARK-013 Trial Insights: Jaime Merchan, MD, shared insights from the LITESPARK-013 trial, which evaluated belzutifan for advanced clear cell renal cell carcinoma treatment, in an interview with Targeted Oncology on December 18th, 2024.
-
Challenges in Second-Line Treatment: Minas P. Economides, MD, discussed the challenges and opportunities in renal cell carcinoma treatment, particularly the lack of therapies available in the second-line setting, in the 4th episode of Emerging Experts on February 1st, 2024.
-
Case Study on Lung-Metastatic RCC: Matthew Campbell, MD, MS, moderated a discussion on the treatment of a 61-year-old patient with lung-metastatic renal cell carcinoma during a Case-Based Roundtable® event on November 14th, 2024.
-
ALLO-316 Phase 1 TRAVERSE Trial Results: The phase 1 TRAVERSE trial demonstrated a 50% overall response rate and a 33% complete response rate in CD70-positive advanced RCC with ALLO-316, as reported on November 11th, 2024.
These discussions and research findings underscore the ongoing advancements and the need for further innovation in the treatment of renal cell carcinoma, particularly in addressing the challenges faced in second-line treatment settings.
